| Business Summary | | Aviron
is
a
biopharmaceutical
company
focused
on
the
prevention
of
disease
through
innovative
vaccine
technology.
The
Company
currently
is
focusing
its
product
development
and
commercialization
efforts
on
its
lead
product
candidate,
FLUMIST,
an
investigational
live
virus
vaccine
delivered
as
a
nasal
mist
for
the
prevention
of
influenza.
The
Company's
goal
is
to
become
a
leader
in
the
discovery,
development,
manufacture
and
marketing
of
vaccines
that
are
safe,
effective
and
suitable
for
widespread
use.
The
Company's
vaccine
development
programs
are
based
on
techniques
for
producing
attenuated
(weakened)
live
virus
vaccines
and
on
its
proprietary
genetic
engineering
technologies. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Aviron
is
a
biopharmaceutical
company
focused
on
the
prevention
of
disease
through
innovative
vaccine
technology,
particularly
its
lead
product,
FluMist.
For
the
six
months
ended
6/30/01,
revenues
rose
21%
to
$7.9
million.
Net
loss
before
acct.
change
rose
23%
to
$58.1
million.
Revenues
reflect
the
development
and
commercialization
of
FluMist.
Net
loss
reflects
higher
R&D
expenses
due
to
increases
in
development
activities. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| C. Boyd Clarke, 52 Chairman,
Pres, CEO | $934K | $277K | Fred Kurland, 51 Sr.
VP and CFO | 355K | -- | Edward Arcuri, Ph.D., 50 Sr.
VP, Operations | 361K | -- | Harry Greenberg, M.D, 56 Sr.
VP, R&D and CSO | 158K | -- | Carol Olson, 43 Sr.
VP, Commercial Devel. | 374K | 436K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|